Form 8-K - Current report:
SEC Accession No. 0001193125-25-064145
Filing Date
2025-03-26
Accepted
2025-03-26 17:01:43
Documents
15
Period of Report
2025-03-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d936539d8k.htm   iXBRL 8-K 35892
2 EX-99.1 d936539dex991.htm EX-99.1 11161
6 GRAPHIC g936539g0326113844203.jpg GRAPHIC 4947
  Complete submission text file 0001193125-25-064145.txt   184482

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA svra-20250326.xsd EX-101.SCH 2866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE svra-20250326_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE svra-20250326_pre.xml EX-101.PRE 11272
18 EXTRACTED XBRL INSTANCE DOCUMENT d936539d8k_htm.xml XML 3670
Mailing Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746
Business Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 51285113796
Savara Inc (Filer) CIK: 0001160308 (see all company filings)

EIN.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32157 | Film No.: 25774152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)